Axsome Therapeutics Inc. (AXSM) and Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) Comparison side by side

Both Axsome Therapeutics Inc. (NASDAQ:AXSM) and Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axsome Therapeutics Inc. N/A 0.00 28.80M -1.13 0.00
Catabasis Pharmaceuticals Inc. N/A 250.03 25.31M -80.26 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Axsome Therapeutics Inc. and Catabasis Pharmaceuticals Inc.


Table 2 demonstrates the net margins, return on equity and return on assets of Axsome Therapeutics Inc. and Catabasis Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Axsome Therapeutics Inc. 0.00% -310.9% -113.7%
Catabasis Pharmaceuticals Inc. 0.00% -91.2% -76.8%


The current Quick Ratio of Axsome Therapeutics Inc. is 1.5 while its Current Ratio is 1.5. Meanwhile, Catabasis Pharmaceuticals Inc. has a Current Ratio of 10.8 while its Quick Ratio is 10.8. Catabasis Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Axsome Therapeutics Inc.

Analyst Ratings

In next table is given Axsome Therapeutics Inc. and Catabasis Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Axsome Therapeutics Inc. 0 0 0 0.00
Catabasis Pharmaceuticals Inc. 0 0 1 3.00

On the other hand, Catabasis Pharmaceuticals Inc.’s potential upside is 238.68% and its average target price is $19.

Institutional & Insider Ownership

Roughly 12.9% of Axsome Therapeutics Inc. shares are owned by institutional investors while 24.1% of Catabasis Pharmaceuticals Inc. are owned by institutional investors. Insiders owned 30.4% of Axsome Therapeutics Inc. shares. Comparatively, 1.93% are Catabasis Pharmaceuticals Inc.’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Axsome Therapeutics Inc. -12.24% -3.46% 154.72% 145.45% 217.65% 187.23%
Catabasis Pharmaceuticals Inc. 0.2% -21.98% -20.76% -35.96% -75.03% 13.73%

For the past year Axsome Therapeutics Inc. has stronger performance than Catabasis Pharmaceuticals Inc.


Catabasis Pharmaceuticals Inc. beats Axsome Therapeutics Inc. on 6 of the 8 factors.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. The company was founded in 2012 and is based in New York, New York.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis. The company has preclinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. Catabasis Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.